Avenova Sales Push NovaBay Pharma (NBY) Upward; Starboard Bets On Stewart Information (STC)


NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) shares soared 68.70% (or +$1.69) to $4.14 on Friday’s trading session as the company delivered a significant growth in revenue and a narrower loss in its quarterly financial results, driven by an 89% increase – versus the previous quarter – in Avenova sales

For the second quarter 2016, NovaBay posted sales of $2.7 million, a 164% increase year over year, and net loss of ($2.7) million, or ($0.36) per share, compared to net loss of ($4.9) million, or ($1.84) per share in the same period the prior year

NBY stock continued its upward move and surged more than 10% in after-hours trading

NovaBay Pharmaceuticals, which develops and commercializes non-antibiotic anti-infective products for the eye care market, has 9.15M Shares Outstanding, Market Capitalization (intraday) of $37.9M and NBY stock 52-week range is between $1.62 and $15.00 per share



Shares of Stewart Information Services Corp. (NYSE:STC) climbed over 5% to touch a mew 52-week high in the extended session Friday after Starboard Value LP disclosed in a regulatory filing ( SC 13D ) with the U.S. Securities and Exchange Commission (SEC) a 9.9% stake (2,315,000 shares) in the company

STC stock closed in negative territory by 0.43% (or -$0.20) at $46.40, with a total volume of 110,065 shares traded during the day

Stewart Information Services, provides title insurance and real estate transaction related services worldwide, has 23.37M Shares Outstanding, Market Capitalization (intraday) of $1.08B and STC stock one-year range is from $30.34 to $46.82 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/